SARS-CoV-2 as an Oncolytic Virus Following Reactivation of the Immune System: A Review

Int J Mol Sci. 2023 Jan 24;24(3):2326. doi: 10.3390/ijms24032326.

Abstract

The effects SARS-CoV-2 inflicts on human physiology, especially in patients who developed COVID-19, can range from flu-like symptoms to death, and although many lives have been lost during the pandemic, others have faced the resolution of aggressive neoplasms that once proclaimed a poor prognosis following traditional treatments. The purpose of this review was to analyze several fortunate case reports and their associated biomolecular pathways to further explore new avenues that might provide oncological treatments in the future of medicine. We included papers that discussed cases in which patients affected by COVID-19 suffered beneficial changes in their cancer status. Multiple mechanisms which elicited a reactivation of the host's immune system included cross-reactivity with viral antigens and downregulation of neoplastic cells. We were able to identify important cases presenting the resolution/remission of different aggressive neoplasms, for which most of the time, standard-of-care treatments offered little to no prospect towards a cure. The intricacy of the defense mechanisms humans have adopted against cancer cells through the millennia are still not well understood, but SARS-CoV-2 has demonstrated that the same ruinous cytokine storm which has taken so many lives can paradoxically be the answer we have been looking for to recalibrate the immunological system to retarget and vanquish malignancies.

Keywords: COVID-19; Hodgkin’s; NK cells; SARS-CoV-2; lymphoma; oncolytic virus; tumor reduction; tumor remission.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Humans
  • Immune System
  • Oncolytic Viruses*
  • SARS-CoV-2

Grants and funding

This research received funding for publication from the “Fondo Semilla” of UAG’s Research Directorate.